Skip to main content

Advertisement

SpringerLink
Log in

The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

The following paper describes a collaboration between the Centers for Disease Control and Prevention and five Emerging Infections Program sites to develop a comprehensive population-based approach to monitoring human papillomavirus (HPV) vaccine impact on cervical cancer precursors and associated HPV genotypes. The process of establishing this novel monitoring system is described, and development details such as enumeration of sources for reporting cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ, approaches to case ascertainment, electronic reporting, and HPV typing are outlined. Implementation of a feasible and sustainable surveillance system for HPV-associated cervical precancers will enable evaluation of the direct impact of HPV vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, Schwenn M, Huang Y, Giuliano A (2008) Burden of cervical cancer in the United States, 1998–2003. Cancer 113(10 Suppl):2855–2864

    Article  PubMed  Google Scholar 

  2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265

    Article  PubMed  CAS  Google Scholar 

  3. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 56(RR-2):1–24

    Google Scholar 

  4. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) (2010). MMWR 59(20):626–629

    Google Scholar 

  5. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2(10):868–878

    Article  Google Scholar 

  6. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314

    Article  PubMed  CAS  Google Scholar 

  7. Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK, Richards TB (2008) Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 113(10 Suppl):2841–2854

    Article  PubMed  Google Scholar 

  8. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370(9590):890–907

    Article  PubMed  CAS  Google Scholar 

  9. The FUTURE II, Group Study (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927

    Article  Google Scholar 

  10. Mullins R, Wakefield M, Broun K (2008) Encouraging the right women to attend for cervical cancer screening: results from a targeted television campaign in Victoria, Australia. Health Educ Res 23(3):477–486

    Article  PubMed  Google Scholar 

  11. Macansh S (2001) The role of the New South Wales Pap test register in monitoring the cervical screening process in New South Wales. N S W Public Health Bull 12(4):99–102

    Article  PubMed  Google Scholar 

  12. Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D, Pinner R (2001) Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 7(1):92–99

    Article  PubMed  CAS  Google Scholar 

  13. National vaccination coverage among adolescents aged 13-17 years–United States, 2006 (2007) MMWR 56(34):885–888

  14. National, state, and local area vaccination coverage among adolescents aged 13–17 years–United States, 2008 (2009) MMWR 58(36):997–1001

  15. National and state vaccination coverage among adolescents aged 13 through 17 years–United States, 2010 (2011) MMWR 60(33):1117–1123

  16. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3):621–632

    Article  PubMed  CAS  Google Scholar 

  17. Rauscher GH, Johnson TP, Cho YI, Walk JA (2008) Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev 17(4):748–757

    Article  PubMed  Google Scholar 

  18. Dasbach EJ, Elbasha EH, Insinga RP (2006) Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28:88–100

    Article  PubMed  Google Scholar 

  19. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13(1):28–41

    Article  PubMed  Google Scholar 

  20. Garnett GP, Kim JJ, French K, Goldie SJ (2006) Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24(Suppl 3):S178–S186

    Google Scholar 

  21. Insinga RP, Glass AG, Rush BB (2004) Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 191(1):105–113

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the following other members of the HPV-IMPACT Working Group/Emerging Infections Network collaborators: Arthur Reingold and Gretchen Rothrock (California Emerging Infections Program); and William Schaffner, MD (Vanderbilt University—Tennessee Emerging Infections Program). We also gratefully acknowledge Stuart Berman (National Center for HIV, viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention), Eileen Dunne (Division of STD Prevention, Centers for Disease Control and Prevention), and Mona Saraiya (Division of Cancer Prevention and Control, Centers for Disease Control and Prevention) for their expert contribution in the planning and design of the project.

Author information

Authors and Affiliations

  1. Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS E-02, Atlanta, GA, 30333, USA

    Susan Hariri

  2. Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA

    Suzanne E. Powell & Lauri E. Markowitz

  3. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

    Elizabeth R. Unger

  4. STD Control Branch, California Department of Health, Richmond, CA, 94804, USA

    Heidi M. Bauer

  5. Center for Community Health and Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

    Nancy M. Bennett

  6. Departments of Medicine and Preventive Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Karen C. Bloch

  7. Division of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

    Linda M. Niccolai

  8. HIV/STD/TB Program, Division of STD, Oregon Department of Human Services, Portland, OR, USA

    Sean Schafer

Authors
  1. Susan Hariri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth R. Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suzanne E. Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heidi M. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nancy M. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karen C. Bloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Linda M. Niccolai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sean Schafer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lauri E. Markowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The HPV-IMPACT Working Group

Corresponding author

Correspondence to Susan Hariri.

Additional information

The HPV-IMPACT Working Group members: Ina Park, MD, MS Erin Whitney, MPH, and Sharon Jotblad, MPH (California Department of Public Health, STD Control Branch); James Hadler, MD, Robert Heimer, PhD, Pamela Julian, MPH, James Meek, MPH (Yale University School of Medicine, Connecticut Emerging Infections Program), and Lynn Sosa, MD (Connecticut Department of Public Health); Ghinwa Dumyati, MD, Mary Scahill and Denisse Licon, MPH (University of Rochester—New York Emerging Infections Program); Nasreen Abdullah MD, MPH, Rob Laing, MPH (Oregon Department of Human Services); Diane Levine, BS, RN, MPH, Manideepthi Pemmaraju, MBBS, MPH, Chasiety Turner, MPH (Vanderbilt University—Tennessee Emerging Infections Program).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hariri, S., Unger, E.R., Powell, S.E. et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 23, 281–288 (2012). https://doi.org/10.1007/s10552-011-9877-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-011-9877-6

Keywords

Search

Navigation